Last updated: July 17, 2026

Application No. 16/972,873

Modified Nucleobases with Uniform H-Bonding Interactions, Homo- and Hetero-Basepair Bias, and Mismatch Discrimination

Final Rejection

Filed

Dec 07, 2020

Priority

Jun 08, 2018 — provisional 62/763,299 +2 more

Examiner

LEE, ANDREW P

Art Unit

1691

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Carnegie Mellon University

OA Round

2 (Final)

Interview Optional

— +23.5% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 48% grant rate with +23.5% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 585 resolved cases, 2023–2026

Examiner Intelligence

LEE, ANDREW P View full profile →

Grants 48% of resolved cases

Career Allowance Rate

284 granted / 585 resolved

-11.5% vs TC avg

Strong +24% interview lift

Without

With

+23.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

36 currently pending

Career history

638

Total Applications

across all art units

Statute-Specific Performance

§101

0.2%

-39.8% vs TC avg

§103

69.6%

+29.6% vs TC avg

§102

2.9%

-37.1% vs TC avg

§112

10.3%

-29.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 585 resolved cases

Prosecution Timeline

Dec 07, 2020

Application Filed

Aug 28, 2025

Non-Final Rejection mailed

Sep 18, 2025

Interview Requested

Oct 01, 2025

Applicant Interview (Telephonic)

Oct 03, 2025

Examiner Interview Summary

Feb 27, 2026

Response Filed

Jun 09, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/597,729

Patent 12655142

4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES

4y 4m to grant Granted Jun 16, 2026

17/280,075

Patent 12642856

DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN

5y 2m to grant Granted Jun 02, 2026

17/334,872

Patent 12642795

MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS

5y 0m to grant Granted Jun 02, 2026

16/342,730

Patent 12629371

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

7y 1m to grant Granted May 19, 2026

18/631,891

Patent 12616683

COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS

2y 0m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

48%

Grant Probability

72%

With Interview (+23.5%)

3y 3m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 585 resolved cases by this examiner. Grant probability derived from career allowance rate.